Heart valve cardiomyocytes of mouse embryos express the serotonin transporter SERT

Biochemical and Biophysical Research Communications

Volumn 377, Issue 2, 2008, Pages 419-422

  Pavone, Luigi Michele ^a   Spina, Anna ^a   Muto, Roberta Lo ^a   Santoro, Dionea ^a   Mastellone, Vincenzo ^b   Avallone, Luigi ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Connexin 43; Cre recombinase; Heart valve development; Immunohistochemistry; Islet1; Serotonin transporter (SERT)

Indexed keywords

BETA GALACTOSIDASE; CONNEXIN 43; SEROTONIN TRANSPORTER;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; HEART DEVELOPMENT; HEART MUSCLE CELL; HEART VALVE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

ANIMALS; BETA-GALACTOSIDASE; CONNEXIN 43; EMBRYO, MAMMALIAN; GENE KNOCK-IN TECHNIQUES; HEART VALVES; HOMEODOMAIN PROTEINS; MICE; MICE, MUTANT STRAINS; MYOCYTES, CARDIAC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 55549111179     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.09.152     Document Type: Article

References (34)

1. Frishman W.H., and Grewall P. Serotonin and the heart. Ann. Med. 32 (2000) 195-209
2. Nebigil C.G., and Maroteaux L. A novel role for serotonin in heart. Trends Cardiovasc. Med. 11 (2001) 329-335
3. Cote F., Fligny C., Fromes Y., Mallet J., and Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 10 (2004) 232-238
4. Ni W., and Watts S.W. 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol. 33 (2006) 575-583
5. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., and Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337 (1997) 581-588
6. Rothman R.B., and Baumann M.H. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther. 95 (2002) 73-88
7. Horvath J., Fross R.D., Kleiner-Fisman G., Lerch R., Stalder H., Liaudat S., Raskoff W.J., Flachsbart K.D., Rakowski H., Pache J.C., Burkhard P.R., and Lang A.E. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. 19 (2004) 656-662
8. Paraskevaidis I., Parissis J.T., Fountoulaki K., Filippatos G., and Kremastinos D. Selective serotonin re-uptake inhibitors for the treatment of depression in coronary artery disease and chronic heart failure: evidence for pleiotropic effects. Cardiovasc. Hematol. Agents Med. Chem. 4 (2006) 361-367
9. Rajamannan N.M., Caplice N., Anthikad F., Sebo T.J., Orszulak T.A., Edwards W.D., Tajik J., and Schwartz R.S. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J. Heart Valve Dis. 10 (2001) 827-831
10. Nebigil C.G., Hickel P., Messaddeq N., Vonesch J.L., Douchet M.P., Monassier L., György K., Matz R., Andriantsitohaina R., Manivet P., Launay J.M., and Maroteaux L. Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function. Circulation 103 (2001) 2973-2979
11. Hu X.Q., and Zhang L. Chronic hypoxia suppresses pharmacomechanical coupling of the uterine artery in near-term pregnant sheep. J. Physiol. 499 (1997) 551-559
12. Sieber-Blum M., Reed W., and Lidov H.G. Serotoninergic differentiation of quail neural crest cells in vitro. Dev. Biol. 99 (1983) 352-359
13. Sari Y., and Zhou F.C. Serotonin and its transporter on proliferation of fetal heart cells. Int. J. Dev. Neurosci. 21 (2003) 417-424
14. Noorlander C.W., Ververs F.F., Nikkels P.G., van Echteld C.J., Visser G.H., and Smidt M.P. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 3 (2008) e2782
15. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., and Friedman J.M. National birth defects prevention study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N. Engl. J. Med. 356 (2007) 2684-2692
16. Pavone L.M., Mithbaokar P., Mastellone V., Avallone L., Gaspar P., Maharajan V., and Baldini A. Fate map of serotonin transporter-expressing cells in developing mouse heart. Genesis 45 (2007) 689-695
17. Zhuang X., Masson J., Gingrich J.A., Rayport S., and Hen R. Targeted gene expression in dopamine and serotonin neurons of the mouse brain. J. Neurosci. Methods 143 (2005) 27-32
18. Soriano P. Generalized lac-Z expression with the ROSA26 Cre reporter strain. Nat. Genet. 21 (1999) 70-71
19. Cai C.L., Liang X., Shi Y., Chu P.H., Pfaff S.L., Chen J., and Evans S. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev. Cell 5 (2003) 877-889
20. Laugwitz K.L., Moretti A., Lam J., Gruber P., Chen Y., Woodard S., Lin L.Z., Cai C.L., Lu M.M., Reth M., Platoshyn O., Yuan J.X., Evans S., and Chien K.R. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433 (2005) 647-653
21. Gelb B.D. Genetic basis of congenital heart disease. Curr. Opin. Cardiol. 19 (2004) 110-115
22. Schoen F.J. Cardiac valves and valvular pathology: update on function, disease, repair, and replacement. Cardiovasc. Pathol. 14 (2005) 189-194
23. Shworak N.W. Angiogenic modulators in valve development and disease: does valvular disease recapitulate developmental signaling pathways?. Curr. Opin. Cardiol. 19 (2004) 140-146
24. Yavarone M.S., Shuey D.L., Tamir H., Sadler T.W., and Lauder J.M. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 47 (1993) 573-584
25. Gustafsson B.I., Tommeras K., Nordrum I., Loennechen J.P., Brunsvik A., Solligard E., Fossmark R., Bakke I., Syversen U., and Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 111 (2005) 1517-1522
26. Fox M.A., Andrews A.M., Wendland J.R., Lesch K.P., Holmes A., and Murphy D.L. A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. Psychopharmacology (Berl.) 195 (2007) 147-166
27. Mekontso-Dessap A., Brouri F., Pascal O., Lechat P., Hanoun N., Lanfumey L., Seif I., Benhaiem-Sigaux N., Kirsch M., Hamon M., Adnot S., and Eddahibi S. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113 (2006) 81-89
28. Levi R.J. Serotonin transporter mechanisms and cardiac disease. Circulation 113 (2006) 2-4
29. Hansson S.R., Mezey E., and Hoffman B.J. Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 89 (1999) 243-265
30. Moretti A., Lam J., Evans S.M., and Laugwitz K.L. Biology of Isl1+ cardiac progenitor cells in development and disease. Cell. Mol. Life Sci. 64 (2007) 674-682
31. Ikeda K., Tojo K., Otsubo C., Udagawa T., Kumazawa K., Ishikawa M., Tokudome G., Hosoya T., Tajima N., Claycomb W.C., Nakao K., and Kawamura M. 5-Hydroxytryptamine synthesis in HL-1 cells and neonatal rat cardiomyocytes. Biochem. Biophys. Res. Commun. 328 (2005) 522-525
32. Fukumoto T., Blakely R., and Levin M. Serotonin transporter function is an early step in left-right patterning in chick and frog embryos. Dev. Neurosci. 27 (2005) 349-363
33. Buznikov G.A., Peterson R.E., Nikitina L.A., Bezuglov V.V., and Lauder J.M. The pre-nervous serotonergic system of developing sea urchin embryos and larvae: pharmacologic and immunocytochemical evidence. Neurochem. Res. 30 (2005) 825-837
34. N. Narboux-Nême, L.M. Pavone, L. Avallone, X. Zhuang, P. Gaspar, Serotonin transporter transgenic (SERT(cre)) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs), Neuropharmacology. 2008 Aug 26. (Epub ahead of print).